News

The open-label, multicenter, single-arm Phase II study BIRCH observed that atezolizumab shrank tumors in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease expressed

In either the single or multiple ascending dose arms of the double-blind, randomized clinical trial, CAT-2054 was well-tolerated with no serious adverse events (AEs) observed. In the multiple

Plegridy is a new molecular entity, resulting from the application of pegylation technology and it offers a new combination of demonstrated efficacy, a favourable safety profile consistent with

As part of the deal, SIFI will be responsible for managing all promotion, marketing and commercial activities in those locations for Iluvien, Alimera’s sustained release intravitreal injection to

The randomized, parallel-group, double-blind, placebo-controlled Kinect 3 trial includes around 240 subjects with moderate to severe tardive dyskinesia and an underlying diagnosis of mood disorder, schizophrenia or schizoaffective

As part of the deal, Janssen will secure rights to develop and commercialize ADC-1013, an agonistic fully human monoclonal antibody, that targets CD40, an immuno-stimulatory receptor found on

As part of the three-year deal, several collaborative studies will be conducted in tumor types such as gastroesophageal adenocarcinoma, pancreatic adenocarcinoma and hepatocellular carcinoma. Under the deal, the

This study evaluated the safety and technical feasibility of a single treatment of vonapanitase via a drug-delivery catheter on atherosclerotic human arteries. The data indicate that catheter-based treatment

The phase 3 trial is designed as a randomized, double-blind, placebo-controlled study of about 400 HLA-A2 positive subjects, which will be conducted at about 120 sites in the